Scarica l'app Stockscreener
13.78
1.64%
-0.23
Dopo l'orario di chiusura:
13.82
0.04
+0.29%
Precedente Chiudi:
$14.01
Aprire:
$14.01
Volume 24 ore:
1.04M
Relative Volume:
0.90
Capitalizzazione di mercato:
$1.37B
Reddito:
-
Utile/perdita netta:
$-44.84M
Rapporto P/E:
-28.37
EPS:
-0.4858
Flusso di cassa netto:
$-44.23M
1 W Prestazione:
-21.21%
1M Prestazione:
-13.82%
6M Prestazione:
+52.60%
1 anno Prestazione:
+192.57%
Intervallo 1D:
$13.58
$14.37
Intervallo di 1 settimana:
$13.36
$17.90
Portata 52W:
$4.64
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Confronta SPRY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| SPRY | 13.78 | 1.37B | 0 | -44.84M | -44.23M | -0.4858 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
William Blair Analysts Increase Earnings Estimates for SPRY - MarketBeat
What is Leerink Partnrs' Forecast for SPRY FY2024 Earnings? - MarketBeat
Emily Leonard - Global Legal Chronicle
Oliver Hodgkiss - Global Legal Chronicle
ALK’s Licensing Agreement with ARS Pharmaceuticals - Global Legal Chronicle
Royce & Associates LP Purchases 45,755 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
(SPRY) On The My Stocks Page - Stock Traders Daily
What is Leerink Partnrs' Estimate for SPRY FY2027 Earnings? - MarketBeat
Q4 EPS Estimate for ARS Pharmaceuticals Boosted by Analyst - MarketBeat
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term - Yahoo Finance
NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES - PR Newswire
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2024 Earnings Call Transcript - Insider Monkey
GSA Capital Partners LLP Boosts Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals earnings missed by $0.06, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals’ Strong Q3 2024 Highlights - TipRanks
Deerfield management sells ARS Pharmaceuticals shares for $10.14 million - Investing.com India
Deerfield management sells ARS Pharmaceuticals shares for $10.14 million By Investing.com - Investing.com Canada
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
ARS Pharma Launches Groundbreaking Needle-Free Epinephrine Spray, Secures $465M Deal | SPRY Stock News - StockTitan
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings - Benzinga
ARS Pharmaceuticals inks global deal for epinephrine product By Investing.com - Investing.com Canada
ARS Pharmaceuticals inks global deal for epinephrine product - Investing.com
ARS Pharmaceuticals announces agreement with ALK to commercialize neffy - Yahoo Finance
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray - Yahoo! Voices
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m - Yahoo Finance
ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week HighTime to Buy? - MarketBeat
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 - Yahoo Finance
ARS Pharmaceuticals Announces Exclusive Agreement with - GlobeNewswire
ARS Pharma Lands $465M Global Deal for Needle-Free Allergy Drug neffy® | SPRY Stock News - StockTitan
Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet - MSN
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) - The Manila Times
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
ARS Pharmaceuticals (SPRY) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Institutional investors control 35% of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) and were rewarded last week after stock increased 10% - Simply Wall St
The Physician-Patient Alliance for Health & Safety Expands Board of Advisors with Five Healthcare Industry Leaders, Enhancing Commitment to Patient Safety and Innovation - GlobeNewswire Inc.
ARS Pharmaceuticals Announces Conference Call and Webcasts - GlobeNewswire
ARS Pharmaceuticals Sets Q3 Earnings Call, Plans Major Healthcare Conference Tour | SPRY Stock News - StockTitan
William Blair Has Positive Forecast for SPRY FY2024 Earnings - MarketBeat
(SPRY) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Raymond James & Associates Invests $2.97 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $24.00 Consensus Target Price from Brokerages - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of “Buy” by Analysts - Defense World
Here's Why 'Trend' Investors Would Love Betting on ARS Pharmaceuticals, Inc. (SPRY) - MSN
Allspring Global Investments Holdings LLC Invests $2.58 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals shares a new treatment for allergic reactions - KATV
New Data on Needle Free Epinephrine Spray Presented at ACAAI 2024 - Patient Care Online
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data - GlobeNewswire
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - StockTitan
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5%Here's Why - MarketBeat
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):